The Weekly Recap 5/22/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive new funding, launch partnerships, receive regulatory approvals, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2).

Activ Surgical

Partnered with Medical Dynamics to be the company’s exclusive distribution partner in Belgium, the Netherlands, and Luxembourg for ActivSight™. ActivSight Intelligent Light is the first and only modular form-factor with multimodal Advanced Visualization, allowing surgeons to augment their senses using augmented reality overlays.

Adagio Medical

Submitted PMA application to the FDA for its vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia in patients with ischemic or non-ischemic structural heart disease. The submission is supported by the FULCRUM-VT pivotal IDE trial, which enrolled 209 patients and demonstrated 97.4% acute clinical success, 84.3% freedom from ICD shock at six months, low major adverse event rates, and a 78% reduction or elimination of anti-arrhythmic drug use.

Aevice Health

Announced a new collaboration with Cedars-Sinai Medical Center to launch a pediatric at-home asthma monitoring program powered by its smart wearable stethoscope. The AeviceMD is an at-home monitoring device designed to track early signs of asthma and provide clinicians with continuous or on-demand remote monitoring of lung sounds.

Arsenal Medical

Received FDA IDE approval to initiate RADIANT, a pivotal trial evaluating NeoCast™. NeoCast is a novel liquid embolic under development that is designed to achieve pain-free, predictable distal penetration of the middle meningeal artery. 

Asabys Partners

Announced the launch of Asabys Innvierte Tech Transfer, a new fund backed by the Ministry of Science, Innovation, and Universities, through CDTI, and the EIF, with a joint commitment of €74.7M. With a target size of up to €120M, the fund will support the creation and growth of breakthrough companies in biotechnology and medical technologies, with a strong focus on technology transfer from universities, hospitals, and research centers.

Cagent Vascular

Announced the successful completion of the first human-use cases with the SerranatorⓇ SONIC Intravascular Lithotripsy System and the closing of a $41M Series D financing round. The round, co-led by U.S. Venture Partners (USVP) and Astoria Health Investors, funds the global REMODEL II pivotal trial and commercial launch of the SONIC IVL System.

Elixir Medical

Announced four-year results from the BIOADAPTOR randomized controlled trial comparing its DynamX coronary bioadaptor system to the Medtronic Resolute Onyx DES, highlighting durable clinical outcomes with DynamX. Investigators reported no new target lesion failure or cardiovascular death events between years three and four, while the system maintained a very low plateauing rate of adverse events compared to the continued annual increase seen with drug-eluting stents.

Endologix

Acquired the Pounce™ Thrombectomy System from Surmodics, closing the deal on May 18, 2026. Pounce, a clinically differentiated mechanical thrombectomy system for peripheral arterial clots, enables the company to support a broader continuum of care for patients with peripheral vascular disease and complements the company’s existing vascular intervention portfolio for the physicians who treat them.

Galvanize Therapeutics

Received FDA 510(k) clearance for the AliyaⓇ EX Generator, expanding the Aliya PEF portfolio by enabling treatment across a broader range of lesion sizes with an ablation zone up to seven times larger. Aliya EX maintains the core attributes of the platform’s pulsed electric field technology, including predictable non-thermal ablation, a favorable safety profile, compatibility with existing workflows and therapies, and potential immune activation.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-52226-lsi-alumni-achievements-driving-medtech-and-healthtech-forward 

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care. Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality. To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape. Defining the Endovascular Procedure Landscape Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, periphe...
Read more